Nothing Special   »   [go: up one dir, main page]

SG11201408153YA - Prostate-specific membrane antigen antibody drug conjugates - Google Patents

Prostate-specific membrane antigen antibody drug conjugates

Info

Publication number
SG11201408153YA
SG11201408153YA SG11201408153YA SG11201408153YA SG11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA
Authority
SG
Singapore
Prior art keywords
international
drug conjugates
antibody drug
san diego
amino acid
Prior art date
Application number
SG11201408153YA
Other languages
English (en)
Inventor
Richard S Barnett
Feng Tian
Anna-Maria A Hays Putnam
Marco Gymnopoulos
Nick Knudsen
Andrew Beck
Ying Sun
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of SG11201408153YA publication Critical patent/SG11201408153YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201408153YA 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates SG11201408153YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656883P 2012-06-07 2012-06-07
PCT/US2013/044850 WO2013185117A1 (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Publications (1)

Publication Number Publication Date
SG11201408153YA true SG11201408153YA (en) 2015-01-29

Family

ID=48699944

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408153YA SG11201408153YA (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates
SG10201702176XA SG10201702176XA (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201702176XA SG10201702176XA (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Country Status (14)

Country Link
US (2) US10800856B2 (zh)
EP (2) EP2858676B1 (zh)
JP (1) JP6425650B2 (zh)
KR (1) KR102143664B1 (zh)
CN (3) CN104619349B (zh)
AU (2) AU2013270686B2 (zh)
CA (1) CA2874854C (zh)
DK (1) DK2858676T3 (zh)
ES (1) ES2725329T3 (zh)
IL (3) IL235895B (zh)
MX (3) MX363116B (zh)
NZ (2) NZ703298A (zh)
SG (2) SG11201408153YA (zh)
WO (1) WO2013185117A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3590541B1 (en) 2012-05-15 2021-08-11 Concortis Biosystems, Corp Drug-conjugates and uses thereof
ES2984397T3 (es) * 2012-06-19 2024-10-29 Ambrx Inc Conjugados de fármaco de anticuerpo anti-CD70
KR102178606B1 (ko) 2013-03-15 2020-11-13 자임워크스 인코포레이티드 세포독성 및 유사분열-억제 화합물, 및 이를 사용하는 방법
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
RU2016134258A (ru) 2013-10-15 2018-02-28 Сорренто Терапьютикс Инк. Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
EP3087091B1 (en) 2013-12-27 2021-10-20 Zymeworks Inc. Var2csa-drug conjugates
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
EP3607996B1 (en) 2014-04-25 2023-01-04 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer
JP6258523B2 (ja) 2014-04-25 2018-01-10 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ抗体−薬物複合体および癌の処置のためのその使用
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CN107849090A (zh) 2015-01-28 2018-03-27 索伦托医疗有限公司 抗体药物偶联物
US20180177890A1 (en) * 2015-02-15 2018-06-28 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method thereof, and use thereof
HUE057906T2 (hu) * 2015-08-14 2022-07-28 Remegen Biosciences Inc Kovalens kötõcsoportok ellenanyag-hatóanyag konjugátumokban és eljárások elõállításukra és alkalmazásukra
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
KR20220147721A (ko) * 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3065137A1 (en) 2017-06-02 2018-12-06 Ambrx, Inc. Methods and compositions for promoting non-natural amino acid-containing protein production
FI3773910T3 (fi) * 2018-03-29 2024-08-29 Ambrx Inc Humanisoituja eturauhasspesifisen membraaniantigeeni (psma) -vasta-aineen ja lääkkeen konjugaatteja
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
CA3076714C (en) * 2019-09-29 2021-06-15 Mabplex International, Ltd. Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
JP7252333B2 (ja) * 2019-09-29 2023-04-04 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 酸法による抗体薬物複合体中間体の調製方法及びその応用
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
WO2024155627A1 (en) 2023-01-16 2024-07-25 Ambrx, Inc. Anti-cd70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US971A (en) 1838-10-08 Mode of pbeventing dust from rising from threshing-machines when in
US7850A (en) 1850-12-24 Improvement in the manufacture of starch from maize
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DK1490483T3 (en) 2001-04-19 2015-09-07 Scripps Research Inst In vivo incorporation of unnatural amino acids
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
CA2508939A1 (en) 2002-12-22 2004-07-15 The Scripps Research Institute Protein arrays
EP1756166A4 (en) 2004-04-19 2008-08-27 Proscan Rx Pharma DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
JP4806680B2 (ja) * 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
WO2006050262A2 (en) 2004-11-01 2006-05-11 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN108047086B (zh) * 2004-12-22 2023-06-16 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途
CA3005835C (en) * 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2007009935A (es) 2005-02-18 2007-10-10 Medarex Inc Anticuerpos monoclonales que carecen de residuos fucosilo contra antigeno membranal especifico de prostata (psma).
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
JP5185813B2 (ja) * 2005-04-26 2013-04-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 癌免疫治療のための組成物および方法
KR20140084242A (ko) * 2005-06-20 2014-07-04 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
MX2009006617A (es) * 2006-12-18 2009-07-24 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
PT2326350E (pt) * 2008-09-08 2013-12-10 Psma Dev Company L L C Compostos para matar células cancerosas resistentes a taxano, que expressam psma
JP5694171B2 (ja) * 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
ES2690993T3 (es) * 2011-05-27 2018-11-23 Ambrx, Inc. Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos
US20150080559A1 (en) * 2011-05-27 2015-03-19 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates

Also Published As

Publication number Publication date
KR20150023563A (ko) 2015-03-05
MX2014015029A (es) 2015-03-03
IL235895A0 (en) 2015-01-29
CN104619349A (zh) 2015-05-13
IL235895B (en) 2018-05-31
NZ713941A (en) 2017-02-24
WO2013185117A1 (en) 2013-12-12
NZ703298A (en) 2016-04-29
CN104619349B (zh) 2018-07-10
US10800856B2 (en) 2020-10-13
US20150152190A1 (en) 2015-06-04
ES2725329T3 (es) 2019-09-23
AU2013270686A1 (en) 2015-01-22
EP3536700A1 (en) 2019-09-11
SG10201702176XA (en) 2017-04-27
MX363116B (es) 2019-03-11
IL268538B (en) 2020-11-30
EP2858676B1 (en) 2019-03-13
AU2017200877B2 (en) 2018-08-30
DK2858676T3 (da) 2019-05-13
JP6425650B2 (ja) 2018-11-21
IL268538A (en) 2019-09-26
MX2023010485A (es) 2023-09-18
AU2013270686B2 (en) 2016-11-10
CN116514899A (zh) 2023-08-01
CN108727466A (zh) 2018-11-02
JP2015521590A (ja) 2015-07-30
EP2858676A1 (en) 2015-04-15
AU2017200877A1 (en) 2017-03-02
CN108727466B (zh) 2023-04-28
IL258937B (en) 2019-08-29
MX2019002732A (es) 2023-02-23
IL258937A (en) 2018-06-28
CA2874854C (en) 2023-03-14
KR102143664B1 (ko) 2020-08-11
CA2874854A1 (en) 2013-12-12
US20220033518A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201408347UA (en) Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201807188VA (en) Modified cells for immunotherapy
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201807912SA (en) Vaccine against rsv
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines